bevacizumab + enzastaurin hydrochloride
Phase 1Completed 0 watching 0 views this week💤 Quiet
33
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Unspecified Adult Solid Tumor, Protocol Specific
Conditions
Unspecified Adult Solid Tumor, Protocol Specific
Trial Timeline
Nov 1, 2006 → Sep 1, 2012
NCT ID
NCT00550927About bevacizumab + enzastaurin hydrochloride
bevacizumab + enzastaurin hydrochloride is a phase 1 stage product being developed by Eli Lilly for Unspecified Adult Solid Tumor, Protocol Specific. The current trial status is completed. This product is registered under clinical trial identifier NCT00550927. Target conditions include Unspecified Adult Solid Tumor, Protocol Specific.
Hype Score Breakdown
Clinical
10
Activity
5
Company
10
Novelty
3
Community
2
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00550927 | Phase 1 | Completed |
Competing Products
20 competing products in Unspecified Adult Solid Tumor, Protocol Specific
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| DJ-927 + capecitabine | Daiichi Sankyo | Phase 1 | 33 |
| E7389 + E7389 + E7389 | Eisai | Phase 1 | 33 |
| SHR-1916 | Jiangsu Hengrui Medicine | Phase 1 | 33 |
| Pembrolizumab | Merck | Phase 2 | 52 |
| PI3K inhibitor BKM120 + docetaxel | Novartis | Phase 1 | 33 |
| bevacizumab + cyclophosphamide + imatinib | Novartis | Phase 1 | 33 |
| capecitabine/oxaliplatin/bevacizumab/RAD001 (XELOX-A-Ev) | Novartis | Phase 1 | 33 |
| warfarin | Novartis | Phase 1 | 33 |
| RLY-1971 | Roche | Phase 1 | 33 |
| Domvanalimab + Zimberelimab | Gilead Sciences | Phase 1 | 32 |
| BEZ235 + MEK162 | Pfizer | Phase 1 | 32 |
| Utomilumab + ISA101b | Pfizer | Phase 2 | 51 |
| Irinotecan | Pfizer | Phase 1 | 32 |
| Ixabepilone + Sunitinib | Pfizer | Phase 1 | 32 |
| ixabepilone + lapatinib ditosylate | Bristol Myers Squibb | Phase 1 | 32 |
| carboplatin + irinotecan hydrochloride | Bristol Myers Squibb | Phase 1 | 32 |
| intoplicine | Sanofi | Phase 1 | 32 |
| apomine | Sanofi | Phase 1 | 32 |
| apomine | Sanofi | Phase 1 | 32 |
| Sorafenib | Bayer | Phase 2 | 49 |